Overview

• In a 72-week study, the highest orforglipron dose delivered 10.5% average weight loss versus 2.2% on placebo and lowered hemoglobin A1C.
• Lilly reported Q2 2025 revenue of $15.6 billion, up 38% year over year, led by Mounjaro and Zepbound.
• The stock rose more than 4% intraday Tuesday following the data release.
• The company said the top-line results provide a full package to seek global approvals, including a filing to the FDA.
• The update follows a roughly 14% selloff on Aug. 7 after an earlier readout, with payer limits and intensifying competition continuing to influence the drug’s commercial outlook.